Actas dermo-sifiliograficas
Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study.
M Mansilla-Polo, M Pons-Benavent, P Fernández-Crehuet, E Vilarrasa, C Albanell-Fernández, E Morales-Tedone, F Rausell-Félix, R Alcalá-García, M Matellanes-Palacios, G Martín-Ezquerra, F Alfageme, C Ciudad-Blanco, M T López-Villaescusa, J M Segura-Palacios, J C Pascual-Ramírez
Published: 202510.1016/j.ad.2025.104531
Abstract
BACKGROUND: Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European Medicines Agency (EMA) for the treatment of hidrade…
Preview only. Read the full abstract at the source